The Reference-scaled Average Bioequivalence (RSABE) Approach
We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…
Certara2025 年 7 月 1 日
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
2025 年 6 月 30 日 Drug development is increasingly defined by its complexity. Teams must navigate rising…
Certara2025 年 6 月 30 日
Maintain & Adapt Pharma Market Access Digital Tools Using Feedback
Maintain the credibility of your pharma market access digital tools through continuous updates based on…
Certara2025 年 6 月 30 日
Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power
2025 年 6 月 16 日 RADNOR, PA – 2025 年 6 月 16 日 – Certara, Inc. （纳斯达克股票代码：CERT), a…
Certara2025 年 6 月 16 日
Certara Reports First Quarter 2025 Financial Results
RADNOR, PA— 2025 年 5 月 5 日-- Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development,…
Certara2025 年 5 月 5 日
Certara Announces Second Annual Certainty U.S. Event
Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…
Certara2025 年 4 月 22 日
How to Use Fix Tips for Better Clinical Data Issue Management
2025 年 4 月 15 日 Prior to submission to any regulatory agency, standardized study data is evaluated using at…
Certara2025 年 4 月 15 日
